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Abstract
Prevalence of autoimmune diseases is increasing. Antibodies are responsible for the humoral
type of adaptive immune responses, glycoprotein structure and produced by B lymphocytes.
Failure of Immunologic self-tolerance due to environmental and genetic factors may
predipose the development of autoimmunity. Self-antigens are either tolerogenic or ignored.
Central tolerance occurs at immature T and B lymphocytes in the thymus and bone marrow.
Peripheral tolerance occurs at mature lymphocytes encounter self-antigens in peripheral
tissues. Negative selection, regulatory T cells, anergy, activation-induced cell death, immune
suppression, receptor editing are examples of important steps of immune tolerance. B lym-
phocytes that produce antibodies which bind self-antigen with medium/low affinity escape
from anergy and those antibodies are called as natural autoantibodies but the other ones
with high affinity are undergo anergy, The natural antibodies have play critical roles as;
discrimination foreign from self, auto-multireactivity, regulate the immunomodulation,
maintain tissue homeostasis. Natural autoantibodies work as the templates for the produc-
tion of pathogenic autoantibodies which has high affinity, switch the class and diverse
somatically under proper conditions. Pathogenic autoantibodies can protect or cause diseases
via neutralization of self-antigens, opsonization, antibody-dependent cellular cytotoxicity,
activation of the complement system, pro-inflammatory and anti-inflammatory effect.
Keywords: physiology, function, structure, autoantibody
1. Introduction
Autoimmune diseases have been increased for the past decades worldwide [1, 2].The preva-
lence of autoantibodies induced autoimmune diseases is over 2.5% [3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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distribution, and reproduction in any medium, provided the original work is properly cited.
Failure of immunologic tolerance may cause the development of autoimmune response and
then autoimmune disease [4, 5].
The cause of autoimmune diseases is an association of genetic tendency and environmental
factors cause alteration the immune regulatory genes by diver’s mechanisms as epigenetics. In
autoimmune diseases pathogenesis, both cellular (as in multiple sclerosis) and humoral (as in
systemic lupus erythematosus (SLE)) type of the adaptive immune system takes a role. An
autoimmune response does not inevitably signify the autoimmune disease [5, 6].
In most of autoimmune diseases, the autoantibodies could been found but not all. Even in
some autoimmune diseases, the autoantibodies signify not autoimmune disease risk, but also
the level of the autoantibodies signifies the severity. By autoantibodies, we can understand
immunologic tolerance failure and pathogenesis mechanisms [7–15].
Autoantibodies are self-reactive antibodies. The self-antigens may be found in all cell types
(e.g. chromatin, centromeres) and those autoimmune diseases is systemic or be highly specific
for a specific cell type in one organ of the body (e.g. thyroglobulin in cells of the thyroid gland)
and those autoimmune diseases is organ-specific. The self-antigens can be in proteins, nucleic
acids, carbohydrates, lipids structure [16]. Immune tolerance is succeed by various mecha-
nisms, occurred at both central and peripheral organs.
2. Autoantibody structure
An antibody molecule and also autoantibody are include of four polypeptide chains; com-
posed of a pair of identical heavy (H) and light (L) chains. Molecular weight of light chain is
25 kDa and heavy chain is 50–70 kDa. The four chains joint together as a Y shaped. Each light
chain is bound to one heavy chain, and the two heavy chains are bound to each other by
disulfide bonds between two cysteine amino acid.
The antigen-binding site of chains that diverse at different antibody is called as the variable (V)
regions and composed of amino acid N-terminal domains of the heavy and light chains. The
part next to the V region is called the constant (C) region. A light chain is made up of one V and
one C region, and a heavy chain has one V and three (at IgG, IgA) or four (at IgM, IgE) C
regions. Each of them is 110 amino acids in length and fields into a characteristic three-
dimensional shape called immunoglobulin (Ig). There are three hypervariable regions or CDRs
at each variable region of the heavy chain (VH) and of the light chain (VL) which is just 6–10
amino acids in length. CDR3 is the greatest variability of three hypervariable region, at the
junction of the V and C regions [4, 5] Figure 1.
Fab fragment (fragment antigen binding) is composed of a bonded whole light chain (with one
V and one C region) and a heavy chain’s V and first C region and recognizes the antigen. The
Fc fragment (fragment crystalline) is the remaining region of heavy chain. Each antibody
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contains two identical Fab fragments and one Fc fragment. The hinge region is located in the
middle of the Fab and Fc regions and is very bending so helps the two Fab fragment getting
closer to antigen far away. The C-Terminal end of the heavy chain of bound antibodies can
terminate with or without anchoring in the cell membrane, but the C-Terminal end of the light
chain terminates freely without attaching the cell membrane [4, 5].
There are two types of light chains according to C region, called κ and λ. Their functions are
same. 60% of antibodies are κ chains and 40% are λ chains There are five types of heavy chains
also according to C region, called μ, δ, γ, ε and α. Every combination of heavy chain and light
chain is available. Antibodies are classified and entitled according to their heavy chains types
(IgM, IgD, IgG, IgE and IgA) [4, 5].
There is five antibody isotypes with different functions and physical and biological properties,
summarized in Table 1.
1. IgM: Heavy chain type is μ. It has pentamere structure with five Fc fragments where
complement binds. The antigen+ pentamere antibody+ complement bound to five Fc complex
starts strong complement activation and is removed by phagocytic cells or complement medi-
ated lysis. So IgM plays critical role in neutralization but it has relatively low affinity and
cannot penetrate into cells/tissues because of the pentamere structure. Half-life of IgG is
approximately 10 days [4, 5].
2. IgG: Heavy chain type is γ. It has monomere structure and penetration rate is high e.g.
penetare through the placenta There are four classes of IgG: G1, G2, G3 and G4. 65% of total
IgG is G1. G1 and G3 activate complement system if the antigen is protein structure and the
protein antigens are removed by phagocytic cells. G2 and G4 play role if the antigen is
Figure 1. Structure of an antibody molecule (IgG).
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carbohydrate structure. Half-life of IgG is approximately 21 days. Since IgG has high affinity
and high molar concentrations in plasma, it makes neutralization [4, 5, 17]. It also makes
opsonization because of γ receptors of phagocytes. If N-terminal end is N-acetyl glucosamine,
the IgG act as pro-inflammatory and if there is sialic acid then act as anti-inflammatory.
3. IgA: Heavy chain type is α. It has monomere or mostly dimere structure which consists of
two basic units joined by a J chain. There are two classes of IgA: A1 and A2. IgA1 is in the
serum while IgA2 is in secretions as; colostrum, salivary, eye tear, respiratory, digestion and
genital and make neutralization of antigens at the mucosal sites. A2; secretory IgA (sIgA) is
protected from lytic enzymes in the digestion tract by secretory component (SC) which is a
part of the receptor and remains attached to the IgA-dimer [4, 5, 17].
4. IgD: Heavy chain type is δ. It has monomere structure. There are two classes of IgD: soluble
and bound IgD. While function in immunology of soluble IgD is not known yet, IgD that
bound on the cell membrane of newly produced B lymphocytes with IgM, activates of newly
produced B lymphocytes by antigens [4, 5, 17].
5. IgE: Heavy chain type is ε. It has monomere structure. IgE plays role in parasitic infections
and allergic reactions by binding to specific IgE receptors on mast cells and basophiles [4, 5].
3. Physiology of autoantibody
3.1. Physiology of antibody
Antibodies are responsible for the humoral type of adaptive immune responses, glycoprotein
structure and produced by B lymphocytes.
Antigens can directly bind to antigen receptors of specific B lymphocytes. The type of revers-
ible bond is non-covalent as; electrostatic attraction, hydrogen bonds, Van der Waals-, charge
interactions and hydrophobic forces. Membrane–bound antibodies (IgM and IgD type) work
Property IgM IgG IgA IgD IgE
Heavy chain type μ γ α δ Ε
% of total immunglobulin in serum 9 75 15 0.2 0.004
Structure Monomer or pentamer Monomer Monomer or dimer Monomer Monomer
Molecular weight (1000) 900 150 170 or 400 180 190
Complement fixation ++ ++ — — —
Cross the placenta — ++ — — —
Allergic response — — — — ++
Antigen receptor at B cell ++ — — + —
Secretoral response — — ++ — —
Table 1. Physical, biological properties and functions of immunoglobulins.
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as antigen receptors of B lymphocytes (BLR) and can bind to antigens in proteins, lipids,
carbohydrates and nucleic acids structures. T lymphocytes can react antigens just in protein
structure. For an antigen-presenting cells (APC), there is not any necessity to present antigens
to B lymphocytes. Epitopes antigens recognized by T cells are narrow linear peptides from 8 to
20 amino acids [4, 16, 17].
After binding of antigens to the receptors that are membrane- bound antibodies; IgM and IgD
type, B lymphocyte become activated. The clonal expansion which means proliferation of
antigen specific cells follows the activation of B lymphocytes and they differentiate into
antibody-secreting effector cells. The specificity of the naïve B cell membrane-bound antibody
receptors is same with the secreted free antibodies. During their differentiation period, some B
cells may differentiate to produce antibodies with different heavy chain classes (or isotypes)
called as heavy chain class (isotype) switching. After switching, different effector functions can
be monitored. Repeated exposure to an antigen leads to the production of antibodies with
increasing capacity to bind the antigen; called as affinity maturation [4, 18].
Antibodies responses are classified into two based on the requirement for T cell help; as
T-independent or T-dependent
3.1.1. Antibody responses to T-independent antigens
If the structure of antigens is non-protein as polysaccharides, lipids, nucleic acids and others
antibody responses evoke without the helper T cells participation. These non-protein antigens
cannot bind to MHC molecules consequently cannot be detected by T cells.
For immunoglobulin receptor mediated signal transduction in B lymphocytes, the bringing
together of two or more antigen molecules in an aggregate (cross-linking), or repeating epi-
topes of one antigen molecule is needed for antigen binding to membrane bound antibody of
the B cell. Multivalent epitope (multiple identical epitopes) as in polysaccharide and lipid
antigen can make cross-link many antigen receptors on a specific B cell consequently stimulate
proliferation, differentiation and antibody production of B lymphocytes [4, 19].
3.1.2. Antibody responses to T-dependent antigens
Most soluble protein antigens cannot make cross-link because they do not contain multivalent
epitope so cannot stimulate their proliferation and differentiation of B lymphocytes. Antigen-
presenting cells process and helper T lymphocytes remember the protein [5].
Stimulations of two or more protein antigens lead at least three changes in B lymphocytes to
improve the interaction of these B cells with helper T lymphocytes.
The changes are:
1. Increased expression of B7 co-stimulator,
2. Increased expression of cytokine receptor
3. Reduced expression of chemokine receptors.
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The T cell activation by B cell requires antigen recognition and co-stimulation:
1. Antigen recognition: B lymphocytes work as antigen-presenting cells (APCs); B lympho-
cytes may bind, internalize and process the antigen protein, and present multiple different
peptides of that protein to T lymphocyte.
2. Co-stimulation: The helper T cells are stimulated by B7 molecules as co-stimulator expressed
by B cells.
CD40 ligand (CD40) and cytokines are expressed by CD4+ helper T lymphocytes after activa-
tion. CD40 ligand; a surface protein delivers the co-stimulatory signal in B cells and interacts
with CD40 on the surface of B lymphocytes. Attachment of CD40 and cytokines stimulate B
cell clonal expression and antibody production. Class switching and affinity maturation are
also stimulated by helper T lymphocytes [4, 5, 19].
After B lymphocytes proliferation and differentiation into antibody-secreting plasma cells, the
antibodies enter the blood through lymphoid follicle. Some plasma cells move to bone marrow,
live at the bone marrow for months or years and continue to produce antibodies afterwards
antigen is removed. These antibodies supply a rapid response when they meet with same
antigen. The humoral immune response decreases physiologically by time because of
programmed B cell death. But a small number of activated cells differentiate into memory
cells, which “freeze” in a state for a very long time [4, 18, 19]. When the body encounter with
the same antigen, the memory cells quickly change into antibody-secreting plasma cells and
produce immunoglobulins. The two advantages of memory cells;
1. Shorter reaction day: instead of five or more days, it takes one or two.
2. B memory cells differentiate with class switch and somatic hypermutation so in case of
reinfection, only memory cells with higher affinities and class switch are selected which are
completely same with the B cell receptors of the original infection. Recurring antigen stimula-
tion causes to helper T lymphocytes increase consecutively antibody increase with heavy chain
class switching and affinity increase [17, 19].
3.2. Stimuli for generation of autoantibody
Failure of immunologic tolerance can cause the development of autoimmunity. With a genetic
background, intolerance can be triggered by environmental factors as sunlight, drugs,
chemicals, and infectious agents [5].
1. Genetic factors: Immunologic tolerance failure is multifactorial and genetic factors are just
one of the cause. For example, the relative risk of having autoimmune disease is 5–50 times
higher in siblings of affected individuals than in unrelated ones. Multiple genes; mostly
MHC predispose to autoimmune disease and genetic predisposition is detected in many
autoimmune diseases. For example, individual with HLA-DR4 gene can be suffered from
rheumatoid arthritis but not everyone [5, 6].
2. Environmental factors: İnfections can cause the autoimmune diseases by activating self-
reactive lymphocytes. The mechanism is like that an infection lead to a local immune
response and activation of APCs. Activated APCs secretes co-stimulators - cytokines and
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stimulate self-reactive T cells which react with self-antigens in the tissue [4]. Some peptide
antigens of microbes are similar to self-antigens, so leads to cross-reactions; called as
molecular mimicry [6]. For example; the antibodies against Porphyromonas gingivalis; a
periodontal pathogen were increased before RA onset and had a relation with RA [20–23].
Microorganisms related autoimmune diseases are listed in Table 2.
Sun lights can trigger lupus diseases. Many drugs as procainamide, hydrocarbon pristine,
hydralazine, chlorpromazine, methyldopa, quinidine, minocycline and nitrofurantoin can trig-
ger autoimmunity or autoimmune disease through ANAs and ANCAs. Many chemical agents
include heavy metals as mercury, gold, and cadmium, pesticides, herbicides, hydrazine can
trigger autoimmunity [5].
In organ-specific autoimmune diseases, such as thyroiditis, type 1 diabetes mellitus and pri-
mary biliary cirrhosis, autoantibodies can be stimulated by infection of the target organ,
through molecular mimicry [16, 24]. In systemic autoimmune diseases, such as systemic lupus,
autoantibodies can be triggered by genetic factors. For example; a nuclear autoantibodies
produced by antigenic drive from excessive release of death cells antigens and enhanced by
intrinsic abnormalities in B or T cells [16, 24].
3.3. Production of autoantibody
3.3.1. Immunologic tolerance
The immune system can differentiate self from non-self [5]. Immunologic tolerance is lack of
response to self-antigens that encounter with lymphocytes [6]. The recognition of self is a
special set of immune events that all constituents of the organism take a role and may be
interrupted by environmental and genetic factors [25–29]. There are three possible immune
responses according to antigen type, after antigen encounter with the lymphocytes which has
the receptors for a specific antigen;
1. Active immune response: Due to the active lymphocytes and antigen type is called immu-
nogenic. For example, most of non-self-antigens
2. Tolerance: Due to inactive or killed lymphocytes and antigen type is called tolerogenic. For
example, self-antigens
Microorganism Related autoimmune diseases
Streptococcus pyogenes Rheumatoid fever
Escherichia coli Primary biliary cirrhosis
Shigella spp. Reiter syndrome
Hepatitis B Multiple sclerosis
Coxsackie B4 Type 1 diabetes mellitus
Cytomegalovirus Scleroderma
Table 2. Infections related with autoimmune diseases.
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3. Ignorance: The antigen cannot either stimulate immunity or induce tolerance. This situa-
tion is called as ignorance. For example, self-antigens [4, 5].
Immune tolerance is set of immune events, operating both at central immune organs and
peripheral ones.
1. Central tolerance happens at immature Tand B lymphocytes encounter self-antigens in the
thymus and bone marrow.
2. Peripheral tolerance happens at mature lymphocytes encounter self-antigens in peripheral
tissues [4, 5].
3.3.2. T lymphocyte tolerance
3.3.2.1. Central T lymphocyte tolerance
The immature T cells die by apoptosis, whenever encounter with self-high avidity protein
antigens in the thymus. The immature lymphocytes in the thymus can recognize both self
and non-self-antigens. If a self-antigen high in concentration and avidity meet with immature
lymphocyte, lymphocytes receives signals that trigger apoptosis, finally dies. This is known as
negative selection. Since the self-protein antigens are expressed mainly in thymus because of
transcription factor responsible called AIRE (for autoimmune regulator), they are high in
concentration [4, 19].
Some lymphocytes which escape from negative selection, mature to dangerous self-reactive
T cells with CD4+ T and CD8+ T. They recognize self-antigens through class I and II MHC
molecules [4, 18, 19].
And some other develop into regulatory T cells which regulate mostly suppress both naïve and
memory T cell responses by a cell to cell contact and by down-regulating the expression of
cytokines and co-stimulatory molecules on the antigen-presenting cells. Unfortunately this is
not antigen specific reaction [4, 5, 18, 19].
3.3.2.2. Peripheral T lymphocytes tolerance
1. Anergy: Anergy is the functional inactivation of T lymphocytes occurs whenever level of
the co-stimulators (second signals) is not enough for T cell activation. If level is enough, the
co-stimulatory signal which is taken by CD80 and CD86; interaction of molecules
expressed on the surface of APC or B cells, reacts with CD28 (or other receptors) on the T
cell surface. If T cells with receptors for the self-antigens encounter with sufficient level of
self-antigens (signal 1) but do not receive sufficient signal 2, they may induce long-lived T
cell anergy [4, 5, 18, 19].
2. Deletion: Activation-induced cell death: Repeated activation of mature T lymphocytes by
repeated encountering with the same antigen cause apoptosis and this is called deletion or
activation-induced cell death [4, 18].
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3. Immune suppression: Autoreactive mature T lymphocytes that encounter with self-antigen
may develop into regulatory cells which suppress the self-reactive lymphocytes response
[4, 18, 19].
3.3.2.3. B cell tolerance
If the self-antigens are in structure of polysaccharides, lipids and nucleic acids antigens, they
must induce tolerance in B cell and prevent autoantibody production [4]. The B cell tolerance is
a set of actions and finally ends with the depletion of or inactive autoreactive B cells. These
processes occur at the every stage of B cell [30, 31].
3.4. Central B cell tolerance
When immature B cells encounter with self-antigens in the bone marrow, the B cells are killed
and the process is called as negative selection [4].
When immature B cells recognize self-antigens in the bone marrow, they may activate their
genes of antibodies and start to express a new light chain. These light chains bind to the
previously produced Ig heavy chain to produce a new antigen receptor. This process is called
receptor editing. The mechanisms of B cell tolerance are multifaceted and may involve receptor
editing, controlled migration, and limited availability of BAFF, CD22, Siglec-G, miRNA, and
follicular regulatory T cells [30–33].
3.4.1. Peripheral B cell tolerance
When mature B lymphocytes encounter with high concentration of self-antigens and B cells
producing antibodies that bind with high affinity to self-antigens in peripheral lymphoid
tissues, they become anergic; functionally inactivation. T cell-independent antigens can trigger
strong signals in the B cell. If it is not strong, the B lymphocytes become anergic [30, 34, 35].
3.5. Role of natural autoantibody
Roles of self-reactive B cells are changing according to binding affinities to self-antigens. If self-
reactive B cells produce antibodies with high affinity, they undergo elimination or anergy. But if
self-reactive B cells produce antibodies with medium or low affinity, they may escape from
anergy, even in non-autoimmune individuals [30, 34, 35].Therefore, a significant proportion of
immunoglobulins in healthy individuals are made by these autoantibodies. Most of the medium/
low affinity antibodies are multireactive and recognize both self and non-self-antigens [30, 35].
They are called as natural antibodies or natural autoantibodies [16, 17, 36]. Because of their
multireactivity, the natural antibodies take an important role in the first part of defense against
infections [16, 37] and natural autoantibodies in the development of the B cell repertoire [38].
Most of natural autoantibodies are IgM isotype, polyreactive with moderate and low affinity.
Therefore, they bind to several unrelated antigens. Also there are natural mono-reactive anti-
bodies [16, 36, 39, 40]. Natural autoantibodies are expressed mostly by CD5+ B1 cell which is
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the most common B lymphocytes in the neonatal period and in marginal zone B cells [41, 42].
These B1 lymphocytes actively present antigens [43] and also play an important role in the
pathogenic autoantibodies production of some autoimmune diseases, as rheumatoid arthritis,
Sjögren syndrome, primary antiphospholipid syndrome and systemic lupus [44].
In the infantile periods as an evolutionary process, proteins participate mainly in the building
and protection of the organism from non-self and self-antigens. During evolution period, these
proteins are highly preserved as the autopolyreactive IgM natural autoantibodies (Nabs)
produced mainly by B-1 CD5þ cells [25, 41] and also after class switch, polymeric and mono-
meric IgG isotype antibodies are produced by mostly B2 cells [25, 45].
Natural antibodies take critical roles; such as:
1. Differentiation self from foreign
2. Recognition of self
3. At evolution period, autopolyreactivity
4. First line defense against non-self-antigens; bacterial and viral infections [46].
5. Regulate the immune system protect the system against tolerance breakdown and the
autoimmune diseases.
6. Maintain tissue balance [47]: Up or down regulation of immunotolerance leads to suscep-
tibility/ progressive or protective role in disease as chronic inflammatory disease [48],
cancer [49], cardiovascular disease [50], and certain neurodegenerative conditions [33, 34].
7. Clearance of tissue and cell debris after degradation [51]; Most diseases is resulting the
destruction of tissues/cells which leads to the continuous antigens release. Natural auto-
antibody recognizes antigens in cell debris and can react with specific antigens of target
tissues. In case of chronic inflammation, more natural autoantibody can be stimulated and
some autoantigens can mutate to xenoantigens; after these mutations, more specific path-
ogenic or protective antibodies can be produced [52].
During cell death, some multiple intracellular enzymes as nucleases and proteases are activated
which cause the numerous cellular molecules cleavage; as a consequence, some hidden antigens
are exposed and called as ‘neoepitopes’ or neodeterminants. Most of the neoepitopes are
undergo to tolerance, but some undergo modification; as cleavage, phosphorylation and oxida-
tion. The self-antigens released by dying cells can be changed by ultraviolet light, oxidation or
cleavage by granzyme B [53] delivered by cytotoxic T cells and this change can lead to autoim-
mune responses. In rheumatoid arthritis, cyclic citrullinated peptides autoantibodies (anti-CCP
antibodies) are one of a neoepitope secondary to inflammation [54]. Citrulline is formed by
deamination of the arginine amino acid during inflammation/oxidative stress or apoptosis.
3.6. Generation of pathogenic autoantibody
In specific autoimmune diseases, some of autoantibodies could be detected before beginning of
the disease. For example; in SLE, rheumatoid arthritis, type I diabetes, limbic encephalitis and
primary biliary cholangitis [55].
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Changing from preclinical to clinical autoantibody has certain steps. In genetic predisposed
individuals, autoantibodies are produced by autoreactive cells. These preclinical autoanti-
bodies can stay for months or even years in these individuals. Under proper environmental
conditions, the autoreactive cells would be activated and proliferated. Then, they produce
large amounts of autoantibodies and inflammatory cytokines, which lead to tissue injury and
the clinical symptoms are observed [6].
Natural autoantibodies can provide the templates for the higher-affinity and class-switched
pathogenic autoantibodies, under appropriate conditions [16].
Production of pathogenic autoantibody:
1. Somatic hypermutation: Each antibody can bind at least 2 (IgG, IgD and IgE isotypes) –
maximum 10 epitopes (IgM isotype) of an antigen, which has identical epitopes and are close
enough. If the multiple antigen-antibody bind each other, the total strength of the bond is
much greater than a single one. This is called the avidity of the interaction. The molar concen-
tration of an antigen needed to occupy half the available antibody molecules in a solution is the
dissociation constant (Kd) and used for expression of affinity. The lower the Kd means the
higher the affinity. In a primary immune response, produced antibodies have a Kd in the range
of 106–109 M and after encountering with repeated antigens, the affinity can rises up to 10–
11 M. This increase in antigen-binding strength is called affinity maturation or somatic
hypermutation [4]. Mostly point mutations in the genes responsible for variable regions of
antibody are detected [16]. They happen in the germinal centers of secondary follicles and AID
enzyme that initiate them [17].
2. Class switching: The membrane bound IgM and IgD the antigen receptors of naïve B
lymphocytes. After stimulation, the antigen specific clone B lymphocytes may proliferate and
differentiate into antibody-secreting cells. Some of these B cells may secrete IgM, and some
others may produce antibodies of other heavy chain classes. The change in Ig isotype produc-
tion is called heavy chain class switching. The V regions remains same, specificity of B cells
maintains [4].
The exons encoding the constant regions of all antibody classes on chromosome 14, are placed
with μ (for IgM) nearest to variable region segments, followed by γ (IgG), α (IgA) and ε (IgE).
By a successful VDJ rearrangement, first the nearest constant region which is μ is used,
resulting in the production of IgM [17]. Unmutated or minimally mutated recombined VDJ
gene sequences encode the multi and monoreactive natural IgM antibodies/autoantibodies
[56]. AID deaminates cytidines in immunoglobulin VDJ and switch-region DNA, then ssDNA
nicks, gaps or double-strand breaks are generated. Repair of these lesions involving error-
prone translesion DNA polymerases are made by the B cell DNA and this results in insertions
of point mutations or resolution of double-strand breaks, and hence, class-switch DNA recom-
bination [57]. After class switch with the same variable region, these cells can express IgG if the
exons encoding the γ constant region; IgA if it is α constant region; and IgE if it is ε constant
region. T-lymphocytes and other cells release cytokines influence isotype of class switch [17].
Unmutated natural IgM autoantibodies expressed by B1 cells provide the ‘templates’ for the
high-affinity and class-switched IgG and/or IgA autoantibodies which can cause autoimmune
diseases [49, 58, 59]. Anti-DNA, anti-insulin and anti-IgG (RF) autoantibodies are pathogenic
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high-affinity autoantibodies that undergo somatic hypermutation, class-switch DNA recombi-
nation and antigen driven clonal selection detected at systemic lupus, type 1 diabetes and
rheumatoid arthritis patients [60]. Somatic hypermutation and class-switching [56, 60, 61]
including the expression of activation-induced cytidine deaminase (AID) [62] are associated
with the expansion of B-2 cells.
Class switch and somatic hypermutation are initiated by the same enzyme, AID, in the
germinal centers of secondary follicles parallelly [17].
3. Somatic diversity: Somatic recombination: Antibodies are capable of binding a wide variety of
antigen, since variable region of antibody molecules forms a flat surface field into different
shapes. The epitopes or determinants are the parts of antigens that are recognized by antibodies
based on sequence (linear determinants) or shape (conformational determinants). Some hidden
antigen molecules are exposed after a physicochemical change, called as neodeterminants [4].
Diversity of antibodies is generated by the genetics arrangement of antibody production; unique
molecular random generator. The variable region of an immunoglobulin is formed by both the
heavy and the light chain which are carried on different chromosomes [5]. The variable portion of
the heavy chain is encoded in separated gene segments of three types, V (variable; the number of
gene segments is 65), D (diversity; 27) and J (joining; 6). A complete heavy chain variable region
exon is randomly cobbled together by juxtaposing one V, one D and one J segment by a cut and
paste process at the DNA level by an enzyme complex containing RAG-proteins (recombination
activating gene) which excises intervening DNA, and normal DNA repair proteins directly rejoin
the segments. Light chain genes have just V and J segments, not D [17]. In summary, the diversity
of antigen binding is achieved by mostly V genes and their combination with different D and J
genes. Different antibodies are produced by four different mechanisms as; randomly combining
V-(D)-J segments, randomly combining heavy and light chain, imprecise joining and somatic
hypermutation [4, 17]. Somatic diversity is performed during central B cell intolerance.
4. Genetic abnormalities: Some genetic alterations results clinical autoimmune disease but some
alterations are influenced by environmental factors. For example; single gen knockout and
overexpression lead to clinical autoimmune disease while most of the autoimmune disorders
are polygenic. Three examples of spontaneous or induced genetic alterations lead to clinical
diseases [16].
a. Abnormal survival of autoreactive lymphocytes: Mutations in Fas/CD95 causes over
expression of the B cell stimulator BLyS; BAFF and the antiapoptotic regulator Bcl-2 which
leads the abnormal survival of autoreactive lymphocytes. It causes an autoimmune
lymphoproliferative syndrome/Canale Smith syndrome in humans [16, 63],
b. Defective removal of apoptotic cells: A group of proteins as Mer and serum opsonins (e.g.,
natural IgM antibodies, C1q, serum amyloid P component [SAP] and milk fat globulin
epithelial growth factor-8 [MFGE8]) [64] take role in the removal of apoptotic cells. In Mer
deficiency, macrophages take a proinflammatory signal not an anti-inflammatory one for
ingestion of apoptotic cells. If there is a defective clearance of apoptotic cells in surface
IgM, C1q, SAP and MFGE8, clearance of apoptotic cells leads to postapoptotic necrosis
and/or through lack of engagement with specific inhibitory receptors on the phagocyte. In
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MFG-E8 deficiency, apoptotic cells accumulate in germinal centers and in C1q-deficiency,
apoptotic cells accumulate in the kidney. These deficiencies cause lupus-like diseases [16].
c. Breakdown in the regulation of B cell or T cell activation threshold: If threshold regulators
of cbl-b, PD-1 and Zap-70 and the SLAM cluster in T cells, and Lyn and FcγRIIb in B cells
change genetically, failure of peripheral immune system could happens. If lymphocytes
are more easily activated, they produce more auto-antibodies as in systemic lupus. Muta-
tions of Zap-70 lead to production of RFs as in rheumatoid arthritis [16, 65]. PD-1-defi-
ciency causes lupus in C57BL/6 and myocarditis in BALB/c.
There is some signature autoantibodies cause autoimmune diseases as anti-endomysial anti-
bodies (EMA), anti-gliadin antibodies (AGA). But there is not a specific antibody detected yet
in several autoimmune diseases, as psoriasis [6].
Lymphocytes and APC are strongly activated by type I interferons (interferon-α and β) [66].
Patients with systemic lupus have elevated levels of interferon and autoantibodies as anti-
DNA and Sm/RNP. By binding to chromatin which contains DNA or to Sm/RNP which
contain small nuclear RNAs, they enter cells through the FcγR or B cell receptor. The intracel-
lular Toll-like receptor is activated by nucleic acid which leads to production of interferon and
activation of immune system. The protein antigen stimulates T cells, probably are responsible
for the specificity of the immune response. These are called Toll hypothesis [67].
3.7. Systemic versus organ-specific autoimmune disease
Autoimmune disease can be classified as systemic or organ specific. Systemic autoimmune
diseases (Table 3), involve multiple organs or tissues, whereas organ specific autoimmune
Disease Organ(s) involved Autoantibodies
Systemic lupus
erythematosus
Joints, skin, nervous system, kidneys, blood cells, heart,
lungs
Anti dsDNAb
Anti Sm b
Anti ribosomal P b
Anti RNA helicase
Rheumatoid arthritis Joints, blood, vessels, lungs Anti citrullinated peptides b
Rheumatoid factor
Sjögren’s syndrome Exocrine glands (salivary and lacrimal glands),
kidneys, nerves
Anti Ro60 (SS-A)
Anti Ro52
Anti La (SS-B)
Scleroderma Skin, blood vessels, GI tract, lungs, kidneys Anti topoisomerase I b
Anti fi brillarin (U3 RNP) b
Anti RNA polymerase I b
Anti RNA polymerase III b
Polymyositis Muscles, lungs tRNA synthetases
(Histidyl, alanyl, threonyl, glycyl,
etc.) b
Signal recognition particle b
Table 3. Some systemic autoimmune diseases.
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diseases (Table 4), involve a single organ or tissue. Almost all organs can be affected by either
systemic or organ-specific autoimmune disease [5].
4. Function of autoantibodies; mechanism of protection and cause of
diseases?
The antibodies’ Fab regions bind to antigens and can block/stimulate the effects of them and
the Fc regions can bind to many cells of immune system as phagocytes and complement and
activate diverse effector mechanisms to eliminate these antigens; Fcγ-R (for IgG), Fcα-R (for
IgA), Fcα/μ-R (for IgA and IgM), Fcε-R (for IgE). The effective binding of antigen-antibody
occurs after recognization several IgG molecules. The affinity of the binding is too low with a
single, free antibody. Bigger immune complexes by antigen and several Fc parts of antibodies
causes to rapid internalization for phagocytosis and antigen clearance. Heavy chain class
switching and affinity maturation enhance the protective functions of antibodies. There is an
exception to this rule in mast cells and eosinophils, just binding a free (meaning non-antigen-
complexed) IgE is enough because of their high-affinity Fc-ε-receptors [4, 17].
4.1. Some examples for the functions of antibodies and autoantibodies
1. Neutralization of foreign and self-antigens: Antibodies bind to block, or neutralize the
activity of foreign or self-antigens [4].
Disease Organ(s) involved Autoantibodies
Hashimoto’s thyroiditis Thyroid Thyroid peroxidase
Thyroglobulin
Graves’ disease Thyroid Thyroid-stimulating hormone receptor
Addison’s disease Adrenal glands 2I-hydroxylase
Type I diabetes Pancreatic islet cells Glutamic acid dehydrogenase,
insulin
islet cell antigens
Pemphigus vulgaris Skin Desmoglein 3
Bullous pemphigoid Skin 230 kDa hemidesmosomal antigen
Vitiligo Skin melanocytes Unknown melanocyte antigens
Goodpasture’s syndrome Kidneys, lungs Type VII collagen
Myasthenia gravis Nervous system Acetylcholine receptor
Multiple sclerosis Nervous system Unknown myelin antigens
Pernicious anemia Gastric parietal cells Parietal cell antigens,
intrinsic factor
Primary biliary cirrhosis Bile ducts Dihydrolipoamide acyltransferase and other antigens b
Autoimmune hepatitis Liver Smooth muscle antigens (F-actin)
Table 4. Some organ-specific autoimmune diseases.
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2. Opsonization and phagocytosis: Complex of antibodies with foreign and self-antigens
promote their ingestion by phagocytes (opsonization). When IgG1 and IgG3 isotype anti-
bodies bind to a foreign or self-antigen, their Fc regions bind to a high affinity receptors called
FcγRI (CD64), which are on neutrophils and macrophages. The binding of antibody Fc tails to
FcγRI results in opsonization of antigenic molecules into a vesicle called a phagosome, where
fuse with lysosomes and activates the neutrophil or phagocytes. The activated ones produces
in their lysosomes, large amounts of reactive oxygen intermediates, nitric oxide, and proteo-
lytic enzymes, all of them together destroy the ingested antigenic cells [4].
3. Antibody-dependent cellular cytotoxicity (ADCC): Natural killer (NK) cells produce an Fc
receptor called FcγRIII, which binds to IgG antibodies. The activated NK cells discharge their
granules, which contains proteins that kill the opsonized targets [4]
4. Activation of the complement system: Antigens without antibody, as part of innate immune
response to infection, and antigens with antibody, as part of adaptive immunity can activate
the complement system. The complement system takes role in the elimination of opsonized
antigens [4]. Examples; activation of complement causes diseases at kidneys of systemic lupus
and lupus nephritis patients, fetal loss associated with the antiphospholipid syndrome [68, 69],
autoantibody administration into the transgenic K/BxN mouse of rheumatoid arthritis [70], in
glucose-6-phosphate isomerase patient. In the NZB/W F1 murine model of immune-complex-
mediated lupus nephritis, mice lacking the FcγRγ chain were protected from nephritis, indi-
cating a critical role for FcγRs in tissue inflammation [71].
5. Mucosal immunity.
6. Pro-inflammatory and anti-inflammatory effect: natural polyautoreactive IgM antibodies
can protect from autoimmune diseases [30]. Also IgG isotype autoantibodies has an anti-
inflammatory capacities, according to their IgG subclass and the extent of glycosylation/
sialylation of the Fc glycan linked to Asn297 [71, 72]. These properties regulate the binding of
antibody to a different Fc-receptors [72]. The receptors as FcγRI (CD64), FcγRIIIA (CD16a),
and FcγRIIIB (CD16b) mediate activating signals, but also FcγRIIA and FcγRIIB (CD32)
mediate inhibiting signals. Glycosylated/ sialylated different IgG isotypes antibodies bind to
Fc-receptors for activating and inhibiting with different affinities [72]. According to glycosyla-
tion/sialylation patterns and IgG subclass determine, an autoantibody produces FcγR-
mediated either pro- or anti-inflammatory functions [73]. So glycosylation of autoantibody
can be an important regulator of autoimmune disorders [74]. While IgG isotypes produced
with T cell-dependent reactions were poorly sialylated causes pro- inflammatory, a high degree
of sialylation that mediates anti-inflammatory properties [75]. Activated B cells and plasma
cells regulate both T cell differentiation into follicular helper T cells and cytokine profiles [76].
By stimulation of TLR, B lymphocytes produce different cytokines to dendritic cells [77].
Dendritic cells are the most important antigen-presenting cells to T cell. B cell also present the
antigen to T cell and so promote the proliferation of activated T lymphocytes, the development
of robust T effector responses, and normal T cell memory compartments [78]. TLR-signals in
murine B cells promote IFN-γ production from T cells and control antibody isotype switching
to IgG2 in vivo [77]. The cowork of activated B and T cells is crucial for the antibody responses
and their outcome as pathogenic potential, that is, the antibody class and glycosylation/
sialylation pattern.
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Testing of autoantibodies is diagnostic criteria in many diseases. But, also autoantibodies could
be detected in healthy individuals [79]. Since isotype/subclass and glycosylation pattern is
critical for the pathogenic potential of a particular antibody, it could be helpful for the diag-
nostic analysis. Pathogenic autoantibodies could be produced either by continuous formation
of short-lived plasma cells or through the formation of long-lived plasma cells, or both [80].
Therapeutic treatment available nowadays could suppress B cell activation and short-lived
plasma cell, while do nothing to long-lived plasma cells [81].
By contrast, mice with FcγRIIb knocked out spontaneously develop a lupus like disease [71].
Different isotypes antibodies have different affinities for the four FcγRs. IgG2a has higher
affinity for FcγRIV, leading to inflammatory responses, whereas IgG1 selectively engages
FcγRIIb, leading to inhibitory responses [30]. There is a similar relationships with human
FcγRs and that the ability to protect or induce inflammation will change according to the
isotype of the autoantibody and FcγR engaged.
7. Removal of cell debris: Natural autoantibodies takes role in the removal of cell debris during
inflammation, and autoantibodies to inflammatory cytokines have protective functions against
inflammation [82].
4.2. Mechanisms of autoimmune tissue injury
Immune responses can cause tissue injury and disorders called as hypersensitivity diseases.
Hypersensitivity is a term of excessive or aberrant immune responses [4]. Tissue damage in
autoimmune diseases can occur through several mechanisms, which are similar to three of the
classical types of hypersensitivity reactions [5]:
1. Type II (caused by autoantibodies reactive with cell surface or matrix antigens):
Antibodies against cell and tissue may cause tissue and disease. IgM and IgG antibodies
activate the phagocytosis of cells by binding to complement and Fc receptor- mediated leuko-
cyte [4]. The reactions are caused by antibodies against self-protein antigens. Autoantibodies
generated against cell surface antigens/extracellular matrix proteins may be cytotoxic (type
IIA) or agonistic/antagonistic (type IIB). Autoantibodies to cell surface antigens may initiate
cell destruction by complement- mediated lysis (cell destruction), phagocytosis, or antibody-
dependent cell-mediated cytotoxicity (ADCC) [5]. At Table 5, some examples of antibody-
mediated diseases are given.
Disease Target antigen Mechanism
Pemphigus vulgaris Proteins in intercellular junction of
epidermal cell
Antibody-mediated activation of proteinase, disruption of
intercellular adhesion
Autoimmune
hemolytic anemia
Erythrocytes membrane antigen Opsonization and phagocytosis of erythrocytes
Myasthenia gravis Acetylcholine receptor Antibody inhibits acetylcholine binding
Table 5. Antibody-mediated diseases.
Autoantibodies and Cytokines28
2. Type III (caused by immune complexes):
Autoantibodies can bind to circulating antigens and form immune complexes that deposit in
vessels, tissues and cause tissue injury. Injury is mainly due to leukocyte recruitment and
inflammation [4]. Autoantibodies can cause disease by forming immune complexes with the
circulating antigens. Immune complex formation is a normal process to remove antigens and
to phagocyte through Fc or complement receptors so are prevented their deposition. The
efficiency of uptake of immune complexes by either Fc receptors or CR1 is proportional to the
number of IgG molecules associated in the complex [5]. At Table 6, some examples of immune
complex mediated diseases are given.
3. Type IV (delayed-type hypersensitivity, mediated by T cells):
T cell-mediated disease is caused by CD4 T lymphocytes or by killing of host cells by CD8
CTLs [4]. T cells recognize protein antigen-presenting cells in the context of class II major
histocompatibility complex (MHC) molecules and produce the cytokines interferon γ (IFN-γ),
interleukin 3 (IL-3), tumor necrosis factor (TNF) α, TNF-β, and granulocyte-macrophage
colony-stimulating factor (GM-CSF). Elaboration of “TH1 (a subset of helper T cells) cyto-
kines” leads to macrophage recruitment and activation, enhanced expression of adhesion
molecules, and increased production of monocytes by the bone marrow [5]. At Table 7, some
examples of T cell-mediated diseases are given.
Author details
Neval Yurttutan Uyar
Address all correspondence to: nevaluyar@gmail.com
Mehmet Ali Aydnlar Acibadem University, Istanbul, Turkey
Disease Target antigen Mechanism
Systemic lupus erythematosus DNA, nucleoproteins Complement and Fc region mediated
Polyarteritis nodosa Hepatitis B surface antigen Complement and Fc region mediated
Poststreptococcal glomerulonephritis Streptococcal cell wall antigen Complement and Fc region mediated
Table 6. Immune complex mediated diseases.
Disease Target antigen Mechanism
Rheumatoid arthritis Antigen in joint synovium T cell mediated
Type I diabetes mellitus Islet cell antigen T cell mediated
Table 7. T cell-mediated diseases.
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